Private Wealth Strategies L.L.C. Has $930,000 Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

Private Wealth Strategies L.L.C. lowered its position in shares of iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 15.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,842 shares of the financial services provider’s stock after selling 1,205 shares during the period. iShares Biotechnology ETF accounts for approximately 0.2% of Private Wealth Strategies L.L.C.’s investment portfolio, making the stock its 26th biggest holding. Private Wealth Strategies L.L.C.’s holdings in iShares Biotechnology ETF were worth $930,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Crewe Advisors LLC increased its stake in iShares Biotechnology ETF by 42.9% during the 4th quarter. Crewe Advisors LLC now owns 260 shares of the financial services provider’s stock worth $35,000 after acquiring an additional 78 shares during the period. Apexium Financial LP increased its holdings in iShares Biotechnology ETF by 3.8% in the 4th quarter. Apexium Financial LP now owns 2,223 shares of the financial services provider’s stock valued at $302,000 after buying an additional 82 shares during the period. Jacobi Capital Management LLC raised its position in shares of iShares Biotechnology ETF by 3.7% in the 3rd quarter. Jacobi Capital Management LLC now owns 2,539 shares of the financial services provider’s stock valued at $310,000 after buying an additional 91 shares in the last quarter. PFG Investments LLC lifted its holdings in shares of iShares Biotechnology ETF by 4.8% during the 3rd quarter. PFG Investments LLC now owns 2,013 shares of the financial services provider’s stock worth $246,000 after acquiring an additional 93 shares during the period. Finally, Huntington National Bank boosted its position in shares of iShares Biotechnology ETF by 7.4% during the 3rd quarter. Huntington National Bank now owns 1,450 shares of the financial services provider’s stock worth $177,000 after acquiring an additional 100 shares in the last quarter. 62.45% of the stock is owned by institutional investors and hedge funds.

iShares Biotechnology ETF Stock Performance

iShares Biotechnology ETF stock traded up $0.84 during midday trading on Thursday, reaching $133.35. The company’s stock had a trading volume of 1,923,517 shares, compared to its average volume of 1,731,144. The business has a 50-day moving average price of $132.56 and a 200-day moving average price of $132.40. iShares Biotechnology ETF has a 52 week low of $111.83 and a 52 week high of $141.16.

iShares Biotechnology ETF Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, March 27th. Stockholders of record on Friday, March 22nd were paid a $0.126 dividend. This represents a $0.50 annualized dividend and a dividend yield of 0.38%. The ex-dividend date was Thursday, March 21st.

iShares Biotechnology ETF Profile

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.